STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo tackles resistant lung cancer in early trial
Disease control OngoingThis early-phase study tests a new two-drug combination (sapanisertib plus osimertinib) in about 36 people with advanced EGFR-mutant non-small cell lung cancer that has worsened after standard treatment. The main goal is to find the safest dose and understand side effects. The ap…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
New drug cocktail shows promise against tough cancers
Disease control OngoingThis study tested a combination of two drugs, cediranib and olaparib, in 122 people with advanced or spreading solid tumors, including certain breast, lung, and pancreatic cancers. The goal was to see if the combo could shrink tumors by blocking enzymes that help cancer grow and …
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
New drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests the safety and best dose of two drugs, ceritinib and everolimus, given together to adults with advanced solid tumors or a type of lung cancer called ALK-positive NSCLC. The goal is to see if the combination can stop tumor growth by blocking key enzyme…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:15 UTC
-
New drug combo shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis study tested a combination of two drugs—trametinib (a targeted therapy) and docetaxel (chemotherapy)—in 60 people with advanced KRAS-mutant non-small cell lung cancer whose disease had worsened after one or two prior treatments. The goal was to see if the combination could s…
Matched conditions: STAGE IV LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:02 UTC